To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Cancer: Diagnosis
Tuesday 14th May 2024

Asked by: Ian Byrne (Labour - Liverpool, West Derby)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the proportion of people who are provided a cancer diagnosis within 28 days of their referral for testing.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department is taking steps to reduce cancer diagnosis and treatment waiting times across England, including the time between an urgent general practice referral and the commencement of treatment for cancer for patients. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. Additionally, as outlined in the 2024/25 NHS England Planning Guidance, NHS England is providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.

To help achieve the cancer waiting times standards, NHS England is streamlining cancer pathways. This includes implementing non-symptom specific pathways for patients who present with non-specific symptoms, as well as timed cancer pathways focused on the most challenged pathways, such as lower gastrointestinal and skin cancer. The pathways aim to support improvements in operational performance and patient experience, as well as providing models to support sustainable improvement.

Furthermore, to improve cancer treatment we are maximising the pace of the roll-out of additional diagnostic capacity. We are currently delivering the second year of the three-year investment plan for establishing community diagnostic centres (CDCs). We are ensuring timely implementation of new CDC locations and upgrades to existing CDCs, with capacity prioritised for cancer diagnostics. As of April 2024, 160 CDCs are operational, and have delivered almost 8 million tests, checks, and scans since July 2021. Additionally, we are supporting advances in radiotherapy. Since 2016, we’ve invested £162 million into cutting-edge radiotherapy equipment to replace or upgrade over 100 radiotherapy treatment machines.

We are committed to delivering the best possible outcomes for patients, and our approach is seeing success. Almost 344,000 people received their first cancer treatment in the 12 months to March 2024. Further, 2023/24 is the best year so far for the Faster Diagnosis Standard (FDS), with the latest performance data showing that NHS England hit the FDS target for the second month in a row at 77.3%, above the standard of 75%. We have also reduced the 62 day or over cancer referral to treatment backlog, to pre-pandemic levels.


Written Question
Cancer: Health Services
Tuesday 14th May 2024

Asked by: Ian Byrne (Labour - Liverpool, West Derby)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the proportion of people who receive treatment for cancer within 31 days of a decision to begin that treatment.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department is taking steps to reduce cancer diagnosis and treatment waiting times across England, including the time between an urgent general practice referral and the commencement of treatment for cancer for patients. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. Additionally, as outlined in the 2024/25 NHS England Planning Guidance, NHS England is providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.

To help achieve the cancer waiting times standards, NHS England is streamlining cancer pathways. This includes implementing non-symptom specific pathways for patients who present with non-specific symptoms, as well as timed cancer pathways focused on the most challenged pathways, such as lower gastrointestinal and skin cancer. The pathways aim to support improvements in operational performance and patient experience, as well as providing models to support sustainable improvement.

Furthermore, to improve cancer treatment we are maximising the pace of the roll-out of additional diagnostic capacity. We are currently delivering the second year of the three-year investment plan for establishing community diagnostic centres (CDCs). We are ensuring timely implementation of new CDC locations and upgrades to existing CDCs, with capacity prioritised for cancer diagnostics. As of April 2024, 160 CDCs are operational, and have delivered almost 8 million tests, checks, and scans since July 2021. Additionally, we are supporting advances in radiotherapy. Since 2016, we’ve invested £162 million into cutting-edge radiotherapy equipment to replace or upgrade over 100 radiotherapy treatment machines.

We are committed to delivering the best possible outcomes for patients, and our approach is seeing success. Almost 344,000 people received their first cancer treatment in the 12 months to March 2024. Further, 2023/24 is the best year so far for the Faster Diagnosis Standard (FDS), with the latest performance data showing that NHS England hit the FDS target for the second month in a row at 77.3%, above the standard of 75%. We have also reduced the 62 day or over cancer referral to treatment backlog, to pre-pandemic levels.


Written Question
Cancer: Health Services
Tuesday 14th May 2024

Asked by: Ian Byrne (Labour - Liverpool, West Derby)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the proportion of people of people who are treated within 62 days of referral for cancer treatment.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department is taking steps to reduce cancer diagnosis and treatment waiting times across England, including the time between an urgent general practice referral and the commencement of treatment for cancer for patients. The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. Additionally, as outlined in the 2024/25 NHS England Planning Guidance, NHS England is providing over £266 million in cancer service development funding to Cancer Alliances, to support delivery of the operational priorities for cancer.

To help achieve the cancer waiting times standards, NHS England is streamlining cancer pathways. This includes implementing non-symptom specific pathways for patients who present with non-specific symptoms, as well as timed cancer pathways focused on the most challenged pathways, such as lower gastrointestinal and skin cancer. The pathways aim to support improvements in operational performance and patient experience, as well as providing models to support sustainable improvement.

Furthermore, to improve cancer treatment we are maximising the pace of the roll-out of additional diagnostic capacity. We are currently delivering the second year of the three-year investment plan for establishing community diagnostic centres (CDCs). We are ensuring timely implementation of new CDC locations and upgrades to existing CDCs, with capacity prioritised for cancer diagnostics. As of April 2024, 160 CDCs are operational, and have delivered almost 8 million tests, checks, and scans since July 2021. Additionally, we are supporting advances in radiotherapy. Since 2016, we’ve invested £162 million into cutting-edge radiotherapy equipment to replace or upgrade over 100 radiotherapy treatment machines.

We are committed to delivering the best possible outcomes for patients, and our approach is seeing success. Almost 344,000 people received their first cancer treatment in the 12 months to March 2024. Further, 2023/24 is the best year so far for the Faster Diagnosis Standard (FDS), with the latest performance data showing that NHS England hit the FDS target for the second month in a row at 77.3%, above the standard of 75%. We have also reduced the 62 day or over cancer referral to treatment backlog, to pre-pandemic levels.


Written Question
Cancer: North East
Monday 13th May 2024

Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of findings from the Royal College of Radiologists, published in May, showing a regional disparity in wait times for cancer treatment in 2023, with 11 per cent of patients in England waiting more than 31 days for treatment after the decision to treat had been confirmed, compared to 19 per cent of patients in the North East and Yorkshire.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

According to the latest data, of those 10,328 cancer patients referred for first or subsequent treatment for radiotherapy in March 2024, 89.7% were treated within 31 days. The proportion of patients waiting more than 31 days for radiotherapy treatment in March 2024 was therefore 10.3%. This has decreased by 4.5% since January 2024.

We are aware of regional disparities in wait times for cancer treatment through NHS England’s data, and are considering the findings made by the Royal College of Radiologists. Tackling inequalities in outcomes, experience, and access of cancer diagnostics, including regional disparities, is a key focus of the Government. NHS England has commissioned six new cancer clinical audits in breast cancer, both primary and metastatic, as well as ovarian, pancreatic, non-Hodgkin lymphoma, and kidney cancer. These will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients. The first outcomes of these audits are expected in September 2024.

The Department is working closely with NHS England to make sure we have the right workforce with the right skills up and down the country. In 2023/24, NHS England invested an additional £50 million to increase the number of cancer and diagnostic specialists.

The Government is also backing the NHS Long Term Workforce Plan, with over £2.4 billion over the next five years to fund additional education and training places. The plan sets out an aim to double the number of medical school places in England to 15,000 places a year by 2031/32, and to work towards this expansion by increasing places by a third, to 10,000 a year, by 2028/29.

We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010. Regarding clinical oncology specifically, as of January 2024, there are currently over 1,600 FTE doctors working in the speciality of clinical oncology in National Health Service trusts and other core organisations in England. This is over 30, or 2.2%, more than last year, over 300, or 27.7%, more than 2019, and over 600, 66.5%, more than in 2010. This includes over 900 FTE consultants. This is over 40, or 5.1%, more than last year, over 100, 22.0%, more than in 2019, and over 400, 80.2%, more than in 2010.


Written Question
Radiotherapy: Staff
Monday 13th May 2024

Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure that the 15 per cent shortfall in clinical oncologists, as estimated in the Royal College of Radiologists workforce census, does not impact the operational performance of radiotherapy services.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

According to the latest data, of those 10,328 cancer patients referred for first or subsequent treatment for radiotherapy in March 2024, 89.7% were treated within 31 days. The proportion of patients waiting more than 31 days for radiotherapy treatment in March 2024 was therefore 10.3%. This has decreased by 4.5% since January 2024.

We are aware of regional disparities in wait times for cancer treatment through NHS England’s data, and are considering the findings made by the Royal College of Radiologists. Tackling inequalities in outcomes, experience, and access of cancer diagnostics, including regional disparities, is a key focus of the Government. NHS England has commissioned six new cancer clinical audits in breast cancer, both primary and metastatic, as well as ovarian, pancreatic, non-Hodgkin lymphoma, and kidney cancer. These will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients. The first outcomes of these audits are expected in September 2024.

The Department is working closely with NHS England to make sure we have the right workforce with the right skills up and down the country. In 2023/24, NHS England invested an additional £50 million to increase the number of cancer and diagnostic specialists.

The Government is also backing the NHS Long Term Workforce Plan, with over £2.4 billion over the next five years to fund additional education and training places. The plan sets out an aim to double the number of medical school places in England to 15,000 places a year by 2031/32, and to work towards this expansion by increasing places by a third, to 10,000 a year, by 2028/29.

We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010. Regarding clinical oncology specifically, as of January 2024, there are currently over 1,600 FTE doctors working in the speciality of clinical oncology in National Health Service trusts and other core organisations in England. This is over 30, or 2.2%, more than last year, over 300, or 27.7%, more than 2019, and over 600, 66.5%, more than in 2010. This includes over 900 FTE consultants. This is over 40, or 5.1%, more than last year, over 100, 22.0%, more than in 2019, and over 400, 80.2%, more than in 2010.


Written Question
Radiotherapy: Waiting Lists
Monday 13th May 2024

Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the proportion of cancer patients currently waiting more than 31 days for radiotherapy treatment.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

According to the latest data, of those 10,328 cancer patients referred for first or subsequent treatment for radiotherapy in March 2024, 89.7% were treated within 31 days. The proportion of patients waiting more than 31 days for radiotherapy treatment in March 2024 was therefore 10.3%. This has decreased by 4.5% since January 2024.

We are aware of regional disparities in wait times for cancer treatment through NHS England’s data, and are considering the findings made by the Royal College of Radiologists. Tackling inequalities in outcomes, experience, and access of cancer diagnostics, including regional disparities, is a key focus of the Government. NHS England has commissioned six new cancer clinical audits in breast cancer, both primary and metastatic, as well as ovarian, pancreatic, non-Hodgkin lymphoma, and kidney cancer. These will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients. The first outcomes of these audits are expected in September 2024.

The Department is working closely with NHS England to make sure we have the right workforce with the right skills up and down the country. In 2023/24, NHS England invested an additional £50 million to increase the number of cancer and diagnostic specialists.

The Government is also backing the NHS Long Term Workforce Plan, with over £2.4 billion over the next five years to fund additional education and training places. The plan sets out an aim to double the number of medical school places in England to 15,000 places a year by 2031/32, and to work towards this expansion by increasing places by a third, to 10,000 a year, by 2028/29.

We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010. Regarding clinical oncology specifically, as of January 2024, there are currently over 1,600 FTE doctors working in the speciality of clinical oncology in National Health Service trusts and other core organisations in England. This is over 30, or 2.2%, more than last year, over 300, or 27.7%, more than 2019, and over 600, 66.5%, more than in 2010. This includes over 900 FTE consultants. This is over 40, or 5.1%, more than last year, over 100, 22.0%, more than in 2019, and over 400, 80.2%, more than in 2010.


Non-Departmental Publication (News and Communications)
Medicines and Healthcare products Regulatory Agency

Apr. 30 2024

Source Page: MHRA’s AI regulatory strategy ensures patient safety and industry innovation into 2030
Document: AIaMD (PDF)

Found: delivery directly to the patient.24 AI can also be used to reduce clinician time in preparing for radiotherapy


Select Committee
The Royal College of Radiologists
NHL0064 - NHS leadership, performance and patient safety

Written Evidence Apr. 24 2024

Inquiry: NHS leadership, performance and patient safety
Inquiry Status: Closed
Committee: Health and Social Care Committee (Department: Department of Health and Social Care)

Found: Clinical oncologists treat cancer by prescribing radiotherapy and managing patients’ treatment. 2.Strong


Deposited Papers

Apr. 23 2024

Source Page: I. Universal Credit guidance April 2024 [update of previous guidance, deposited Oct 2023, DEP2023-0791]. 204 docs. II. Letter dated 15/04/2023 from Jo Churchill MP to to the Deposited Papers Clerk regarding documents for deposit in the House libraries. Incl. file list at Annex 1. 9p.
Document: 177._Treated_as_having_LCWRA_and_Day_1_WCA_referrals_V6.0.pdf (PDF)

Found: work - related activity • is awaiting, receiving or recoveri ng from treatment for cancer by way of radiotherapy


Deposited Papers

Apr. 23 2024

Source Page: I. Universal Credit guidance April 2024 [update of previous guidance, deposited Oct 2023, DEP2023-0791]. 204 docs. II. Letter dated 15/04/2023 from Jo Churchill MP to to the Deposited Papers Clerk regarding documents for deposit in the House libraries. Incl. file list at Annex 1. 9p.
Document: 117._New_Style_ESA_only_claims_V6.0.pdf (PDF)

Found: or attend a WCA (for example, being terminally ill , receiving or recovering from chemotherapy or radiotherapy